Literature DB >> 1643259

Characterization of the glucuronide conjugate of cotinine: a previously unidentified major metabolite of nicotine in smokers' urine.

W S Caldwell1, J M Greene, G D Byrd, K M Chang, M S Uhrig, J D deBethizy, P A Crooks, B S Bhatti, R M Riggs.   

Abstract

Recent studies in our laboratories have confirmed that a major unidentified metabolite of nicotine in smokers' urine was susceptible to enzymatic degradation by beta-glucuronidase to afford (S)-(-)-cotinine. In order to establish the identity of this metabolite, the quaternary ammonium conjugate, viz., (S)-(-)-cotinine N-glucuronide, was synthesized. Reaction of methyl 2,3,4-tri-O-acetyl-1-bromo-1-deoxy-alpha-D-glucopyranuronate with (S)-(-)-cotinine at 60 degrees C for 3 days affords the fully protected conjugate as the bromide salt. Deprotection was accomplished in 1 M NaOH overnight at 25 degrees C. The deprotected inner salt was isolated by Dowex-50W cation-exchange chromatography. Electrospray mass spectra of the inner salt revealed the presence of ions with m/z 353 (M + H)+, 375 (M + Na)+, and 391 (M + K)+ as well as ions resulting from loss of water and cleavage of the glycosidic bond. Proton and carbon nuclear magnetic resonance spectra established that the position of glucuronidation was the pyridyl nitrogen. The magnitude of the coupling between H1" and H2" of the sugar ring (8.71 Hz) and nuclear Overhauser enhancements were consistent with the beta-isomer of the glucuronide conjugate. The synthetic (S)-(-)-cotinine N-glucuronide was susceptible to enzymatic hydrolysis by beta-glucuronidase to afford (S)-(-)-cotinine. Application of a cation-exchange high-performance liquid chromatographic method enabled the collection of a fraction containing (S)-(-)-cotinine N-glucuronide from a smoker's urine. The electrospray mass spectrum of this fraction contained ions consistent with the presence of (S)-(-)-cotinine N-glucuronide. The concentrated fraction was subjected to enzymatic hydrolysis by beta-glucuronidase to afford (S)-(-)-cotinine.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1643259     DOI: 10.1021/tx00026a021

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  7 in total

1.  Glucuronidation genotypes and nicotine metabolic phenotypes: importance of functional UGT2B10 and UGT2B17 polymorphisms.

Authors:  Gang Chen; Nino E Giambrone; Douglas F Dluzen; Joshua E Muscat; Arthur Berg; Carla J Gallagher; Philip Lazarus
Journal:  Cancer Res       Date:  2010-09-28       Impact factor: 12.701

2.  Glucuronidation of trans-3'-hydroxycotinine by UGT2B17 and UGT2B10.

Authors:  Gang Chen; Nino E Giambrone; Philip Lazarus
Journal:  Pharmacogenet Genomics       Date:  2012-03       Impact factor: 2.089

3.  Comparison of measured and FTC-predicted nicotine uptake in smokers.

Authors:  G D Byrd; J H Robinson; W S Caldwell; J D deBethizy
Journal:  Psychopharmacology (Berl)       Date:  1995-11       Impact factor: 4.530

4.  Homozygous deletions of UGT2B17 modifies effects of smoking on TP53-mutations and relapse of head and neck carcinoma.

Authors:  Aki Mafune; Takanori Hama; Toshihito Suda; Yutaka Suzuki; Masahiro Ikegami; Chikako Sakanashi; Satoko Imai; Akio Nakashima; Takashi Yokoo; Kota Wada; Hiromi Kojima; Mitsuyoshi Urashima
Journal:  BMC Cancer       Date:  2015-03-31       Impact factor: 4.430

5.  Synthesis and Evaluation of the Anti-Oxidant Capacity of Curcumin Glucuronides, the Major Curcumin Metabolites.

Authors:  Ambar K Choudhury; Suganya Raja; Sanjata Mahapatra; Kalyanam Nagabhushanam; Muhammed Majeed
Journal:  Antioxidants (Basel)       Date:  2015-12-02

6.  Benzoylated uronic acid building blocks and synthesis of N-uronate conjugates of lamotrigine.

Authors:  Aslan M Esmurziev; Arne Reimers; Trygve Andreassen; Nebojsa Simic; Eirik Sundby; Bård Helge Hoff
Journal:  Molecules       Date:  2012-01-16       Impact factor: 4.411

7.  Cotinine: Beyond that Expected, More than a Biomarker of Tobacco Consumption.

Authors:  Valentina Echeverria Moran
Journal:  Front Pharmacol       Date:  2012-10-10       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.